References
- Krishna S, Bustamante L, Haynes RK, et al. HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008;29: 520–527.
- Zeng QP, Zhang PZ. Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 2011;24:110–112.
- Steinbruck L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and G/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 2010;7:337–346.
- Zhou HJ, Wang WQ, Wu GD, et al. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 2007;47: 131–138.
- Rasheed SA, Efferth T, Asangani IA, et al. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 2010;127:1475–1485.
- Du JH, Zhang HD, Ma ZJ, et al. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010;65:895–902.
- Li S, Xue F, Cheng Z, et al. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol 2009;90:513–521.
- Li HM, Long Y, Qing C, et al. Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res 2011;19:149–163.
- Griffin RJ, Williams BW, Koonce NA, et al. Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors. J Oncol 2012;2012:934918.
- Singh NP, Lai HC, Park JS, et al. Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res 2011; 31:4111–4114.
- Buommino E, Baroni A, Canozo N, et al. Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009;27:412–418.
- Liu WM, Gravett AM, Dalgleish AG. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer 2011;128:1471–1480.
- Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:85–101.
- Leon-Bollotte L, Subramaniam S, Cauvard O, et al. S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology 2011;140:2009–2018.
- Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126–140.
- Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma:implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121–2143.
- Shaulian E. AP-1--The Jun proteins: oncogenes or tumor suppressors in disguise?Cell Signal 2010;22:894–899.
- Zhang X, Zhang L, Yang H, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007;67:9425–9434.
- Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006;107:2627–2632.
- Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072–1078.
- Efferth T, Li PC, Konkimalla VS, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13:353–361.